Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0

Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0

Saved in:

Bibliographic Details
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-03-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/3/e006947add1.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
by: Anne Mills, et al.
Published: (2023-06-01)

The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
by: John Barrett, et al.
Published: (2020-10-01)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
by: Raffit Hassan, et al.
Published: (2022-05-01)

Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
by: Deborah Collyar, et al.
Published: (2025-03-01)

Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit
by: Antonia R Sepulveda, et al.
Published: (2020-05-01)

Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review
by: Francesco M Marincola, et al.
Published: (2025-01-01)

Correction: Defining current gaps in quality measures for cancer immunotherapy: consensus report from the society for immunotherapy of cancer (SITC) 2019 Quality Summit
Published: (2020-05-01)

A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy
by: Pedro J Romero, et al.
Published: (2025-03-01)

Addendum for Euro Surveill. 2025;30(30)
by: Eurosurveillance editorial team
Published: (2025-08-01)

Version 3.0
by: Douglas McCormick
Published: (2009-02-01)

IMMUNOTHERAPY FOR MELANOMA
by: E. A. Borobova, et al.
Published: (2017-09-01)

SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy
by: Evan J Lipson, et al.
Published: (2025-06-01)

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
by: Mario Sznol, et al.
Published: (2020-05-01)

Addendum for Euro Surveill. 2025;30(21)
by: Eurosurveillance editorial team
Published: (2025-05-01)

Immunotherapy and delivery systems for melanoma
by: Hui Liu, et al.
Published: (2024-12-01)

Progress and challenges in melanoma immunotherapy
by: LIN Jing, et al.
Published: (2025-07-01)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
by: Yi Lin, et al.
Published: (2020-10-01)

Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee
by: T Peter Kingham, et al.
Published: (2025-06-01)

Tumor-infiltrating lymphocytes for melanoma immunotherapy
by: Oliver Kepp, et al.
Published: (2023-12-01)

Multi-Epitope DC Vaccines with Melanoma Antigens for Immunotherapy of Melanoma
by: Athanasios Seretis, et al.
Published: (2025-03-01)

Addendum
Published: (2025-12-01)

Addendum
Published: (2012-01-01)

Addendum
by: David Haukos
Published: (2016-12-01)

Opportunities, obstacles and challenges of nano-immunotherapy in melanoma
by: Zexing Shan, et al.
Published: (2025-08-01)

Gut markers for metastatic melanoma receiving immunotherapy
by: Guoping Ou, et al.
Published: (2025-07-01)

The significance of tumor microenvironment for immunotherapy in melanoma and non-melanoma skin cancer
by: Taku Fujimura
Published: (2025-08-01)

The role of immunotherapy in the treatment of skin melanoma: a contemporary perspective
by: P. S. Masaeva
Published: (2024-06-01)

Efficiency of ADOPTIVE immunotherapy for melanoma: a case REPORT
by: E. V. Abakushina, et al.
Published: (2016-11-01)

Marked Erythroblast Haemophagocytosis in Association With Immunotherapy for Metastatic Melanoma
by: Tamasine Stewart, et al.
Published: (2025-06-01)

DNA methylation in melanoma immunotherapy: mechanisms and therapeutic opportunities
by: Maya G. Deshmukh, et al.
Published: (2025-04-01)

Translation and psychometric evaluation of Self-Care of Hypertension Inventory Version 3.0 (SC-HI v3.0) in Iranian population
by: Fatemehzahra Naddafi, et al.
Published: (2025-03-01)

Peptide-based PET tracer targeting LAG-3 for evaluating the efficacy of immunotherapy in melanoma
by: Yan Wang, et al.
Published: (2024-07-01)

Association of Antibiotics and Other Drugs with Clinical Outcomes in Metastatic Melanoma Patients Treated with Immunotherapy
by: Manish D. Angrish, et al.
Published: (2021-01-01)

The epiMelanoma test enables plasma-based detection of melanoma and prediction of immunotherapy response
by: Olivia Dumas, et al.
Published: (2025-08-01)

Advances in immunotherapy for uveal melanoma: enhancing efficacy and overcoming resistance
by: Jian Song, et al.
Published: (2025-06-01)

Targeting metabolic reprogramming to overcome immune tolerance in melanoma immunotherapy
by: Qinchen Wang, et al.
Published: (2025-06-01)

Stimuli-Responsive Drug Delivery Systems for Enhanced Melanoma Immunotherapy
by: Zhang G, et al.
Published: (2025-08-01)

Novel Anti-Melanoma Immunotherapies: Disarming Tumor Escape Mechanisms
by: Sivan Sapoznik, et al.
Published: (2012-01-01)

Combined stereotactic radiation therapy and immunotherapy for metastatic uveal melanoma
by: Valeria V. Nazarova, et al.
Published: (2025-05-01)

Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy
by: M. Willemsen, et al.
Published: (2024-12-01)